OncoMatch/Clinical Trials/NCT04210492
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
Is NCT04210492 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies non-drug interventions for non-small cell lung cancer.
The purpose of this trial is to test a deescalated 3-fraction stereotactic body radiotherapy (SBRT) regimen to 45 Gray (Gy) in 3 fractions for centrally located thoracic tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Smilow Cancer Hospital Care Center at Greenwich · Greenwich, Connecticut
- Smilow Cancer Hospital Care Center - Guilford · Guilford, Connecticut
- Smilow Cancer Hospital - Hamden Care Center · Hamden, Connecticut
- Smilow Cancer Hospital · New Haven, Connecticut
- Smilow Cancer Hospital Care Center - Trumbull · Trumbull, Connecticut
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04210492 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages